KYN-101 - ≥98% , CAS No.2247950-73-6

CAS: 2247950-73-6 Cat. No.: K649692 Molecular Weight: 386.42
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
5mg
K649692-5mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$360.90
10mg
K649692-10mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$560.90
25mg
K649692-25mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,040.90
50mg
K649692-50mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,600.90
100mg
K649692-100mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$2,400.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.

In Vitro

KYN-101 (0.5, 1 µM; 24 h) decreases the CYP1A1 mRNA expression in IDO high samples. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

KYN-101 (10 mg/kg; p.o.; daily for 12 days) shows anti-cancer activity in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice) Dosage: 10 mg/kg Administration: P.o.; daily for 12 days Result: Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.

Form:Solid

Specifications

Specifications & Purity
≥98%
Biochemical and Physiological Mechanisms
KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥98%
Names and Identifiers
Molecular Weight 386.42

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Citations of This Product
References
1. Yvhao Xie, Xinxin Li, Qingshi Meng, Jinjun Li, Xin Wang, Liying Zhu, Weiwei Wang, Xiaoqiong Li.  (2024)  Interplay between gut microbiota and tryptophan metabolism in type 2 diabetic mice treated with metformin.  Microbiology Spectrum,      [PMID:39162538] [10.1128/spectrum.00291-24]
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.